 | | Vol. 15.05 – 10 February, 2021 |
| |
|
|
| Researchers engineered human induced pluripotent stem cells (iPSCs) to carry an inducible H3.3-K27M allele in the endogenous locus and studied the effects of the mutation in different disease-relevant neural cell types.
[Cancer Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators presented an authentic midbrain dopamine neuron derivation protocol based on a two-step WNT signaling activation strategy that improved expression of midbrain markers, such as Engrailed-1 while minimizing the expression of contaminating posterior and anterior lineage markers.
[Cell Stem Cell] |
|
|
|
| Scientists generated midbrain dopamine neurons from human embryonic stem cells and manufactured large-scale cryopreserved dopamine progenitors for clinical use.
[Cell Stem Cell] |
|
|
|
| The authors conducted a comprehensive activity-dependent transcriptional and epigenetic profiling of human induced pluripotent stem cell-derived GABAergic neurons similar to those of the early developing striatum.
[Nature Neuroscience] |
|
|
|
| Investigators developed a new approach to derive microglia from human pluripotent stem cells (hPSCs) and built a defined hPSC-derived tri-culture system containing pure populations of hPSC-derived microglia, astrocytes, and neurons to dissect cellular cross-talk along the neuroinflammatory axis in vitro.
[Nature Neuroscience] |
|
|
|
| Scientists revealed the phenotype of neuroblastoma cancer cells by comparing cancer with normal fetal adrenal single-cell transcriptomes.
[Science Advances] |
|
|
|
| Treatment of glioma cells with the dopamine receptor antagonist quetiapine reduced glioma cell self-renewal in vitro and combined treatment of mice with quetiapine and radiation prolonged the survival of glioma-bearing mice.
[JNCI-Journal of the National Cancer Institute] |
|
|
|
| Investigators indicated that OLIG2 was dispensable for diffuse intrinsic pontine glioma (DIPG) growth but regulated the phenotypic switch of DIPG tumor cells.
[Neuro-Oncology] |
|
|
|
| Scientists isolated labeled mutant oligodendrocyte precursor cells by laser-capture microdissection and determined gene expression changes by bulk RNA sequencing and a fluctuation analysis called stochastic profiling, which used RNA-sequencing measurements from random pools of ten mutant cells.
[Cancer Research] |
|
|
|
| Researchers identified a highly conserved lncRNA, Zeb2os, and demonstrated using functional assays that it played an important role in reactive astrogliosis through the Zeb2os/Zeb2/Stat3 axis.
[Cell Reports] |
|
|
|
| Investigators resolved individual exocytic events in developing murine cortical neurons and used classification tools to identify four distinguishable fusion modes: two full-vesicle fusion-like modes that inserted membrane material and two kiss-and-run fusion-like modes that did not.
[Cell Reports] |
|
|
|
| Scientists focused on dihydrofolate reductase (DHFR), a key enzyme in one-carbon metabolism, and demonstrated this enzyme’s overexpression in several human brain tumors and its expression in human brain tumor initiating cells.
[Cancer Letters] |
|
|
|
|
| Investigators review the current understanding of astrocyte interactions with microglia and the vasculature and protective barriers in the central nervous system as well as highlight recent insights into physiologic and reactive astrocyte sub-states identified by transcriptional profiling.
[Immunity] |
|
|
|
| The authors highlight advances in the development and application of gene-based therapies for neurodegenerative diseases and offer a prospective look into this emerging arena.
[Nature Neuroscience] |
|
|
|
|
| Alterity Therapeutics, Ltd. announced the award of a grant from The Michael J. Fox Foundation for Parkinson’s Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson’s disease based on imaging of brain iron.
[Alterity Therapeutics, Ltd.] |
|
|
|
| Yumanity Therapeutics, Inc. provided several updates on its lead clinical-stage program, YTX-7739, in development for the treatment of Parkinson’s Disease.
[Yumanity Therapeutics, Inc.] |
|
|
|
|
| March 10 – 11, 2021
Virtual |
|
|
|
|
|
| | Western University – London, Ontario, Canada |
|
|
|
| | Aarhus University – Aarhus C, Denmark |
|
|
|
| | Columbia University Medical Center – New York City, New York, United States |
|
|
|
| | KTH Royal Institute of Technology – Stockholm, Sweden |
|
|
|
| | Max Planck Institute for Brain Research – Frankfurt am Main, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
